Cargando…
Evaluating clinical impact of a shortened infusion duration for ramucirumab: a model-based approach
PURPOSE: We investigated the impact of infusion duration (30 and 60 min) on the pharmacokinetic profile of ramucirumab using a population pharmacokinetic (PopPK) modeling approach. We also assessed the relationship between infusion rate and incidence of immediate infusion-related reactions (IRRs; oc...
Autores principales: | Gao, Ling, Lau, Yiu-Keung, Wei, Ran, O’Brien, Lisa, Long, Amanda, Piao, Yongzhe, Abada, Paolo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8026424/ https://www.ncbi.nlm.nih.gov/pubmed/33532866 http://dx.doi.org/10.1007/s00280-020-04223-9 |
Ejemplares similares
-
A Prospective Trial Evaluating the Safety of a Shortened Infusion of Ramucirumab in Patients with Gastrointestinal Cancer
por: Hashimoto, Naoya, et al.
Publicado: (2018) -
Population pharmacokinetic meta‐analysis of ramucirumab in cancer patients
por: O'Brien, Lisa, et al.
Publicado: (2017) -
A post-marketing observational study of ramucirumab in patients with gastric cancer in Japan
por: Chen, Yucherng, et al.
Publicado: (2021) -
Stepwise shortening of agalsidase beta infusion duration in Fabry disease: Clinical experience with infusion rate escalation protocol
por: Riccio, Eleonora, et al.
Publicado: (2021) -
Pattern of progression in advanced hepatocellular carcinoma treated with ramucirumab
por: Reig, Maria, et al.
Publicado: (2020)